Tianma Gouteng Yin Formula (TGYF) was reported to have a blood pressure lowering effect, improving clinical symptoms and quality of life in hypertensive patients. This review could not find any randomised controlled clinical trials that compared TGYF to placebo or no treatment. Further research to establish its efficacy is needed.
As no trials could be identified, no conclusions can be made about the role of TGYF in the treatment of primary hypertension. Well-designed randomized controlled studies need to be conducted and published.
Tianma Gouteng Yin Formula (TGYF) is widely used to treat hypertension-related symptoms in clinical practice in East Asia. It has been shown to have a blood pressure lowering effect, reducing total cholesterol, improving clinical symptoms and quality of life, and preventing the occurrence of stroke in hypertensive patients. Understanding the effect of Tianma Gouteng Yin Formula on blood pressure, quality of life and cardiovascular risk factors could be valuable for the management of high blood pressure.
To assess the efficacy and safety of Tianma Gouteng Yin Formula for treating primary hypertension compared to placebo or no treatment.
English databases including Cochrane Central (CCTR), MEDLINE, EMBASE, AMED, CINAHL, IPA, and the Hypertension Group Specialised Register were searched up to July 2011. Chinese databases including Chinese Biomedical Database, TCMonline , Chinese Dissertation Database, CMAC and the Index to Chinese Periodical Literature were searched up to April 2010.
Randomised and quasi-randomised controlled trials that compared TGYF with no treatment or placebo for primary hypertension.
No study was identified which met the inclusion criteria for this review.
No study was identified which met the inclusion criteria for this review.